Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Net Cash Flow data on file, last reported at $182.3 million in Q1 2026.

• Quarterly Net Cash Flow rose 256.5% year-over-year to $182.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $330.7 million (up 15876.67% YoY) and the FY2025 annual result came in at $31.9 million, down 33.35% from the prior year.
• Net Cash Flow rose to $182.3 million in Q1 2026 per DNLI's latest filing, from $114.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $182.3 million in Q1 2026 and bottomed at -$188.5 million in Q1 2022.
• The 5-year median for Net Cash Flow is $16.0 million (2024), against an average of $5.6 million.
• The widest annual swing landed in 2024, when Net Cash Flow soared 503.37%; it then slumped 414.87% in 2025.
• Tracing DNLI's Net Cash Flow over 5 years: stood at $99.4 million in 2022, then slumped by 121.03% to -$20.9 million in 2023, then soared by 503.37% to $84.3 million in 2024, then surged by 35.62% to $114.4 million in 2025, then jumped by 59.4% to $182.3 million in 2026.
• Per Business Quant, the three latest DNLI Net Cash Flow figures stand at $182.3 million (Q1 2026), $114.4 million (Q4 2025), and -$50.2 million (Q3 2025).

Peer Comparison